Abstract

PLASMA LEVELS OF 14-3-3η PROTEIN AND ITS CORRELATION WITH ACTIVITY OF RHEUMATOID ARTHRITIS PATIENTS

Sahar Abdul Sattar Alwan*, Dr. Mayada Noori Iqbal and Ali Hussein Al-Hafidh

Abstract

Back ground: Rheumatoid arthritis (RA) is a chronic inflammatory disease with autoimmune pathogenesis disease that affects about 1.5% of the community. New markers are needed for early diagnosis of rheumatoid arthritis as seronegativity in early rheumatoid arthritis remains a major limitation of both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The 14-3-3η protein may represent biomarker for the detection of RA. Objective: Study aims to investigate about 14-3-3-eta protein as a prospective RA-specific marker that complements both RF and ACPA and increasing their diagnostic value, and their correlation with disease activity and body mass index in the newly diagnosed rheumatoid arthritis. Material and methods: Early diagnosis patients with RA groups 103 (56 new early diagnosis without treatment group; 47early diagnosis with treated group), were included according to American College of Rheumatology (ACR) criteria and 25 subjects as healthy control group. All demographic(Age, Gender, Disease duration and Family history), clinical data(Simple Disease Activity Index in 28 joints "SDAI", Body Mass Index "BMI") and serological data(serum ACPA, CRP, RF, plasma 14-3-3-eta investigated by ELISA methods and ESR was estimated by westren methods were recorded. Results: Rheumatoid Arthritis new early diagnosis without treatment group divided according to RF results (seropositive 36, seronegative 20) and early diagnosis with treated group(seropositive 32, seronegative 15), Mean and SE of plasma14-3-3 ηlevels in patients with RA(26.94+2.47 ng/ml), were significantly higher (P<0.05) among both groups, as compared to healthy control individuals (27.42 + 1.998 ng/ml). Positive Anti-CCP in patients groups 94(91.3%), negative Anti-CCP 9(8.7%) as compare with positive Anti-CCP 0(0.00%) at healthy control group. High significant deference between RF+ve and RF-ve (p<0.01) among 14-3-3-eta and Anti-CCP at both groups except 14-3-3-eta at early treated groups had no significant deference(p=0.077). There was no significant correlation between 14-3-3η levels and SDAI at(P >0.05)in both groups, while significant positive correlation between 14-3-3η levels and BMI in new early diagnosis without treatment group at(P< 0.05). For plasma14-3-3 η diagnostic accuracy in RA; ROC curve analysis comparing patient with RA and control showed no significant AUC(P =0.132)of new early diagnosis without treatment group, the ROC curve yielded a sensitivity of 88.9%, a specificity of 60.0% of new early diagnosis without treatment group. 14-3-3η is an RA key marker that associated with pathogenesis of RA and play an important role for difference between RF+ve and RF-ve among RA patients.

Keywords: Serum14-3-3?; New early RA diagnosis; Disease activity SDAI; Body Mass Index BMI.